Evropska unija - slovenščina - EMA (European Medicines Agency)

sanofi pasteur - hepatitis b surface antigen, diphtheria toxoid, tetanus toxoid, bordetella pertussis antigens pertussis toxoid filamentous haemagglutinin, poliovirus (inactivated) type 1 (mahoney) type 2 (mef-1) type 3 (saukett), haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) conjugated to tetanus protein - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - vaccines, bacterial and viral vaccines, combined - hexacima (dtap-ipv-hb-hib) je indicirano za osnovno in obnovitveno cepljenje dojenčkov in malčkov iz šestih tednih starosti proti davici, tetanus, oslovski kašelj, hepatitis b, otroški ohromelosti in invazivnih bolezni, ki povzroča haemophilus influenzae tipa b (hib). uporaba tega cepiva mora biti v skladu z uradnimi priporočili.

Evropska unija - slovenščina - EMA (European Medicines Agency)

sanofi pasteur europe - filamentous haemagglutinin, haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate), hepatitis b surface antigen, pertussis toxoid, poliovirus (inactivated) type 1 (mahoney strain) produced on vero cells, poliovirus (inactivated) type 2 (mef-1 strain) produced on vero cells, poliovirus (inactivated) type 3 (saukett strain) produced on vero cells, tetanus protein, tetanus toxoid adsorbed on aluminium hydroxide, hydrated, diphtheria toxoid - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - cepiva - hexyon (dtap-ipv-hb-hib) je indicirano za osnovno in obnovitveno cepljenje dojenčkov in malčkov iz šestih tednih starosti proti davici, tetanus, oslovski kašelj, hepatitis b, otroški ohromelosti in invazivnih bolezni, ki povzroča haemophilus influenzae tipa b (hib). uporaba tega cepiva mora biti v skladu z uradnimi priporočili.

Evropska unija - slovenščina - EMA (European Medicines Agency)

lipomed gmbh - cladribine - leukemija, dlakasta celica - antineoplastična sredstva - litak je indiciran za zdravljenje leukemije dlakavice.

Evropska unija - slovenščina - EMA (European Medicines Agency)

merck sharp & dohme b.v. - rotavirusni serotip g1, serotip g2, serotip g3, serotip g4, serotip p1 - immunization; rotavirus infections - vaccines, viral vaccines - rotateq je indiciran za aktivno imunizacijo dojenčkov od šestih tednov do 32 tednov za preprečevanje gastroenteritisa zaradi rotavirusne okužbe. rotateq je treba uporabiti na podlagi uradnih priporočil.

Evropska unija - slovenščina - EMA (European Medicines Agency)

mcm vaccine b.v. - davica toxoid, tetanus toxoid, bordetella oslovskemu kašlju antigenov: oslovskemu kašlju toxoid, nitastih haemagglutinin, pertactin, fimbriae vrste 2 in 3, hepatitis b surface antigen, proizvedene v kvas celice, poliovirus (inaktivirano): tip 1 (mahoney), tip 2 (mef-1), tip 3 (saukett), ki v chicagu celic/ haemophilus influenzae tipa b polysaccharide (polyribosylribitol fosfat) konjugiran na meningococcal beljakovin. - meningitis, haemophilus; poliomyelitis; tetanus; diphtheria; whooping cough; hepatitis b - cepiva - vaxelis (dtap-hb-ipv-hib) je indicirano za osnovno in obnovitveno cepljenje pri dojenčkih in malčkih od starosti 6 tednov, proti davici, tetanus, oslovski kašelj, hepatitis b, otroški ohromelosti in invazivnih bolezni, ki povzroča haemophilus influenzae tipa b (hib). uporaba zdravila vaxelis mora biti v skladu z uradnimi priporočili.

Evropska unija - slovenščina - EMA (European Medicines Agency)

rayner surgical (ireland) limited - ketorolak, phenylephrine - lens implantation, intraocular; pain, postoperative - oftalmologi - omidria je indicirana pri odraslih za vzdrževanje intraoperativne mirodije, preprečevanje intraoperativne mioze in zmanjšanje akutne postoperativne očesne bolečine pri operaciji nadomestitve intraokularne leče.

Evropska unija - slovenščina - EMA (European Medicines Agency)

astellas pharma europe b.v. - enzalutamid - prostatične neoplazme - endokrini terapija - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.

Evropska unija - slovenščina - EMA (European Medicines Agency)

amgen technology (ireland) uc - bevacizumab - carcinoma, renal cell; peritoneal neoplasms; ovarian neoplasms; breast neoplasms; carcinoma, non-small-cell lung; fallopian tube neoplasms - antineoplastična sredstva - mvasi v kombinaciji s kemoterapijo na osnovi fluoropyrimidine je indicirano za zdravljenje odraslih bolnikov z metastatskim rakom debelega črevesa in danke. mvasi v kombinaciji z paclitaxel je določen za prvo linijo za zdravljenje odraslih bolnikov z metastatskim rakom dojke,. za nadaljnje informacije o statusu receptorja človeškega epidermičnega rastnega faktorja 2 (her2) glejte poglavje 5. mvasi, poleg platinum, ki temelji kemoterapijo, je označen za prvo linijo zdravljenja odraslih bolnikih z unresectable napredno, metastatskega ali ponavljajoče se non-small cell lung cancer razen pretežno skvamoznih celic histologija. mvasi in combination with interferon alfa-2a is indicated for first-line treatment of adult patients with advanced and/or metastatic renal cell cancer. mvasi, v kombinaciji z carboplatin in paclitaxel je označena na sprednji strani-line zdravljenje odraslih bolnikov z napredovalim (international federation of porodništva in ginekologije (figo) faze, iiib, iiic in iv) epitelnih jajčnikov, fallopian tube, ali primarni trebušno raka. mvasi, v kombinaciji z carboplatin in gemcitabine ali v kombinaciji z carboplatin in paclitaxel, je indicirano za zdravljenje odraslih bolnikov s prvo ponovitev platinum-občutljive epitelnih jajčnikov, fallopian tube ali primarni trebušno raka, ki še niso prejeli pred terapijo z bevacizumab ali drugih vegf inhibitorji ali vegf receptor-ciljno agenti. mvasi in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor-targeted agents. mvasi, v kombinaciji z paclitaxel in cisplatin, ali, alternativno, paclitaxel in topotecan pri bolnikih, ki ne morejo prejemati platinum terapija je primerna za zdravljenje odraslih bolnikov z vztrajno, periodično, ali metastatskim karcinom materničnega vratu.

Evropska unija - slovenščina - EMA (European Medicines Agency)

samsung bioepis nl b.v. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastična sredstva - aybintio in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. aybintio in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. za nadaljnje informacije o statusu receptorja človeškega epidermičnega rastnega faktorja 2 (her2) glejte poglavje 5. 1 of the smpc. aybintio in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracyclinecontaining regimens in the adjuvant setting within the last 12 months should be excluded from treatment with aybintio in combination with capecitabine. za nadaljnje informacije o statusu her2 glejte poglavje 5. 1 of the smpc. aybintio, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. aybintio, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. 1 of the smpc). aybintio in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. aybintio, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. 1 of the smpc). aybintio, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. aybintio, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. 1 of the smpc). aybintio, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5. 1 of the smpc).

Evropska unija - slovenščina - EMA (European Medicines Agency)

centus biotherapeutics europe limited - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell - antineoplastična sredstva - bevacizumab v kombinaciji s kemoterapijo na osnovi fluoropirimidina je indiciran za zdravljenje odraslih bolnikov z metastatskim karcinomom debelega črevesa ali danke. bevacizumab je v kombinaciji z paclitaxel je določen za prvo linijo za zdravljenje odraslih bolnikov z metastatskim rakom dojke,. za nadaljnje informacije o statusu receptorja človeškega epidermičnega rastnega faktorja 2 (her2) glejte poglavje 5. bevacizumab je v kombinaciji z capecitabine je določen za prvo linijo za zdravljenje odraslih bolnikov z metastatskim rakom dojke, pri katerih zdravljenje z drugimi kemoterapijo možnosti, vključno z taxanes ali anthracyclines se ne šteje za primerno. patients who have received taxane and anthracycline- containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with equidacent in combination with capecitabine. za nadaljnje informacije o statusu her2 glejte poglavje 5. bevacizumab, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. bevacizumab je v kombinaciji z erlotinib, je označen za prvo linijo zdravljenja odraslih bolnikih z unresectable napredno, metastatskega ali ponavljajoče se non-skvamoznih non-small cell lung cancer z epidermalna rastni dejavnik receptorjev (egfr) aktiviranjem mutacije. bevacizumab in combination with interferon alfa-2a is indicated for first-line treatment of adult patients with advanced and/or metastatic renal cell cancer. bevacizumab, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iiib, iiic and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. bevacizumab, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor-targeted agents. bevacizumab je v kombinaciji z paclitaxel in cisplatin, ali, alternativno, paclitaxel in topotecan pri bolnikih, ki ne morejo prejemati platinum terapija je primerna za zdravljenje odraslih bolnikov z vztrajno, periodično, ali metastatskim karcinom materničnega vratu.